All pages
Jump to navigation
Jump to search
- Anticonvulsant
- Anticonvulsant drug
- Anticonvulsant hypersensitivity syndrome
- Anticonvulsant therapy
- Anticonvulsants
- Anticor
- Anticubital fossa
- Anticurare
- Antidepressant
- Antidepressant discontinuation syndrome
- Antidepressants
- Antidepressants in Japan
- Antiderivative
- Antidiabetic
- Antidiabetic drug
- Antidiabetic drugs
- Antidiarrheal
- Antidiarrheals
- Antidiarrhoeal
- Antidiuretic
- Antidiuretic Hormone
- Antidiuretic effect
- Antidiuretic hormone
- Antidopaminergic
- Antidote
- Antidote (patient information)
- Antidotes
- Antidromic
- Antidromic AVRT
- Antidromic AV reentrant tachycardia
- Antidromic atrioventricular reentrant tachycardia
- Antiemetic
- Antiemetics
- Antiepileptic
- Antiepileptic drugs
- Antiepileptics
- Antifebrin
- Antiferromagnetism
- Antifibrinolytic
- Antifibrinolytic Agent
- Antiflatulent
- Antiflex
- Antifolate
- Antifreeze
- Antifreeze (coolant)
- Antifreeze poisoning
- Antifreeze protein
- Antifungal
- Antifungal Drug
- Antifungal agent
- Antifungal drug
- Antifungal medication
- Antifungals
- Antigen
- Antigen-presenting cell
- Antigen-presenting cell vaccine
- Antigen-presenting cells
- Antigen detection test
- Antigen presentation
- Antigen presenting cell
- Antigen presenting cells
- Antigen processing
- Antigenic
- Antigenic determinant
- Antigenic drift
- Antigenic escape
- Antigenic mimicry
- Antigenic shift
- Antigenic variation
- Antigenics Inc.
- Antigens
- Antiglobulin test
- Antiglomerular basement membrane disease
- Antigout
- Antihecticum poterii
- Antihelix
- Antihelminthic
- Antihemophilic Factor
- Antihemophilic Factor (Human)
- Antihemophilic Factor (Human) (patient information)
- Antihemophilic Factor (Recombinant)
- Antihemophilic Factor (Recombinant) (patient information)
- Antihemophilic Factor (human)
- Antihemophilic Factor (recombinant)
- Antihemophilic factor
- Antihemophilic factor (patient information)
- Antihemophilic factor (recombinant)
- Antihemorrhagic
- Antihemorrhoidals
- Antihistamine
- Antihistaminergic
- Antihistamines
- Antihumanism
- Antihydrogen
- Antihypertensive
- Antihypertensive And Lipid-Lowering Treatment To Prevent Heart Attack Trial
- Antihypertensive agent
- Antihypertensive agents
- Antihypertensive and lipid-lowering treatment to prevent heart attack trial
- Antihypertensive drug
- Antihypertensive drugs
- Antihypertensive management
- Antihypertensive medication
- Antihypertensive medications
- Antihypertensive therapies
- Antihypertensive therapy
- Antihypertensives
- Antiinflammatory
- Antilepsin
- Antilirium
- Antilog
- Antimalarial
- Antimalarial drug
- Antimalarial medication
- Antimalarials
- Antimatter
- Antimetabolic agent
- Antimetabolite
- Antimetabolites
- Antimicrobial
- Antimicrobial Prophylaxis for Cancer-Related Infections
- Antimicrobial agent
- Antimicrobial drug
- Antimicrobial peptide
- Antimicrobial peptides
- Antimicrobial prophylaxis
- Antimicrobial prophylaxis in surgery
- Antimicrobials
- Antimicrosomal antibodies
- Antimicrosomal antibody
- Antimicrotubule agent
- Antimigraine
- Antimitochondrial Antibodies
- Antimitochondrial antibodies
- Antimitotic agent
- Antimitotic agents
- Antimonial
- Antimonial cup
- Antimony
- Antimony(III) acetate
- Antimony pentafluoride
- Antimony pentasulfide
- Antimony trifluoride
- Antimony triiodide
- Antimony trioxide
- Antimullerian hormone
- Antimuscarinic
- Antimuscarinics
- Antimycin A
- Antimycobacterial
- Antimycobacterials
- Antimycotic agents
- Antimyelin associated glycoprotein
- Antinaus 50
- Antinauseants
- Antinematodals
- Antineoplastic
- Antineoplastic agents
- Antineoplastic antibiotic
- Antineoplaston
- Antineutrino
- Antineutrophil Cytoplasmic Antibodies
- Antineutrophil cytoplasmic antibodies
- Antineutrophil cytoplasmic antibody
- Antinicotinic
- Antinomy
- Antinuclear Antibody
- Antinuclear antibodies
- Antinuclear antibody
- Antinuclear factor
- Antiobesity
- Antioncogenic
- Antioxid Caplets
- Antioxidant
- Antioxidant-electrophile responsive element gene transcriptions
- Antioxidant Formula
- Antioxidant Ultra Formula
- Antioxidants
- Antioxidants: WACS Study Demonstrates No Significant Benefit From Antioxidants For Preventing CVD
- Antiparallel
- Antiparallel (biochemistry)
- Antiparasitic
- Antiparasitics
- Antiparkinsonian
- Antiparkinsonism
- Antiparticle
- Antiparticles
- Antipater (1st century BC physician)
- Antipater (2nd century physician)
- Antiperiplanar
- Antiperspirant
- Antiphagocytic
- Antiphlogistic
- Antiphospholipid-Antibody Syndrome (APL)
- Antiphospholipid Antibody Syndrome
- Antiphospholipid Syndrome
- Antiphospholipid antibodies
- Antiphospholipid antibody
- Antiphospholipid antibody syndrome
- Antiphospholipid syndrome
- Antiphospholipid syndrome (patient information)
- Antiphospholipid syndrome CT
- Antiphospholipid syndrome MRI
- Antiphospholipid syndrome case study one
- Antiphospholipid syndrome causes
- Antiphospholipid syndrome chest x ray
- Antiphospholipid syndrome classification
- Antiphospholipid syndrome diagnostic criteria
- Antiphospholipid syndrome differential diagnosis
- Antiphospholipid syndrome echocardiography or ultrasound
- Antiphospholipid syndrome epidemiology and demographics
- Antiphospholipid syndrome historical perspective
- Antiphospholipid syndrome history and symptoms
- Antiphospholipid syndrome laboratory findings
- Antiphospholipid syndrome medical therapy
- Antiphospholipid syndrome natural history, complications and prognosis
- Antiphospholipid syndrome other diagnostic studies
- Antiphospholipid syndrome other imaging findings
- Antiphospholipid syndrome overview
- Antiphospholipid syndrome pathophysiology
- Antiphospholipid syndrome physical examination
- Antiphospholipid syndrome primary prevention
- Antiphospholipid syndrome resident survival guide
- Antiphospholipid syndrome risk factors
- Antiphospholipid syndrome secondary prevention
- Antiphospholipid syndrome surgery
- Antiplatelet
- Antiplatelet Therapy to Support PCI (patient information)
- Antiplatelet agent
- Antiplatelet agents
- Antiplatelet agents in Diabetics
- Antiplatelet drug
- Antiplatelet therapy
- Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty 5 (ARMYDA-5) Presented Today at TCT 2007
- Antiplatelet therapy to support PCI
- Antiplatelets: Clopidogrel-to-Ticlopidine Crossover Study Demonstrates Drug Specific Resistance
- Antipokhmelin
- Antiporter
- Antiporters
- Antiprogestin
- Antipropulsive
- Antiproton
- Antiprotozoal
- Antiprotozoal agent
- Antipruritic
- Antipsoriatics
- Antipsychiatry
- Antipsychology
- Antipsychotic
- Antipsychotic (withdrawal)
- Antipsychotic agents
- Antipsychotic drugs
- Antipsychotics
- Antipyretic
- Antipyretic (patient information)
- Antipyretics
- Antipyrine
- Antipyrine/Benzocaine
- Antiretroviral
- Antiretroviral agent
- Antiretroviral drug
- Antiretroviral drugs
- Antiretroviral therapy
- Antiretroviral therapy in pregnancy
- Antirheumatic
- Antirheumatics
- Antisacer
- Antisense
- Antisense RNA
- Antisense mRNA
- Antisense strand
- Antisense therapy
- Antiseptic
- Antiseptic Principle of the Practice of Surgery
- Antiseptic lavage
- Antiseptics
- Antisera
- Antiserotonergic
- Antiserum
- Antisocial
- Antisocial Personality Disorder
- Antisocial behavior
- Antisocial personality disorder
- Antisocial personality disorder (patient information)
- Antispasmodic
- Antispasmodics
- Antistaphylococcal penicillins
- Antistatic agent
- Antistreptococcal Antibodies
- Antistreptococcal antibodies
- Antistreptolysin O
- Antistreptolysin O titer
- Antistreptolysin O titre
- Antisynthetase syndrome
- Antitermination
- Antithrombin
- Antithrombin 3
- Antithrombin 3 deficiency
- Antithrombin III
- Antithrombin III adverse reactions
- Antithrombin III clinical pharmacology
- Antithrombin III clinical studies
- Antithrombin III contraindications
- Antithrombin III deficiency
- Antithrombin III deficiency (patient information)
- Antithrombin III deficiency case study one
- Antithrombin III deficiency causes
- Antithrombin III deficiency classification
- Antithrombin III deficiency cost-effectiveness of therapy
- Antithrombin III deficiency differential diagnosis
- Antithrombin III deficiency epidemiology and demographics
- Antithrombin III deficiency future or investigational therapies
- Antithrombin III deficiency historical perspective
- Antithrombin III deficiency history and symptoms
- Antithrombin III deficiency laboratory findings
- Antithrombin III deficiency medical therapy
- Antithrombin III deficiency natural history, complications and prognosis
- Antithrombin III deficiency other diagnostic studies
- Antithrombin III deficiency overview
- Antithrombin III deficiency pathophysiology
- Antithrombin III deficiency physical examination
- Antithrombin III deficiency prevention
- Antithrombin III deficiency risk factors
- Antithrombin III deficiency screening
- Antithrombin III description
- Antithrombin III dosage and administration
- Antithrombin III dosage forms and strengths
- Antithrombin III drug interactions
- Antithrombin III how supplied storage and handling
- Antithrombin III indications and usage
- Antithrombin III nonclinical toxicology
- Antithrombin III overdosage
- Antithrombin III patient counseling information
- Antithrombin III use in specific populations
- Antithrombin III warnings and precautions
- Antithrombin Therapy During Percutaneous Coronary Intervention (PCI)
- Antithrombin Therapy During Percutaneous Coronary Intervention (PCI) (patient information)
- Antithrombin deficiency
- Antithrombin deficiency, congenital
- Antithrombin references
- Antithrombin therapy to support PCI
- Antithrombotic
- Antithrombotic medication
- Antithrombotic therapy
- Antithyroglobulin antibodies